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innovation provides opportunities for immediate benefit, including survival until 
the next therapy is available, and may uncover new clinical pathways with signifi-
cant cumulative benefit. Recognition of this “option value” for future health and 
research advances is needed.
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Objectives: The 2014 American Society of Clinical Oncology (ASCO) payment 
reform proposal includes value-based adjustments based on performance on qual-
ity, use of/adherence to pathways, and utilization of other healthcare resources. 
The objective of this analysis was to assess current use of QOC metrics in US can-
cer care. MethOds: Medical-oncologists and hematologist/oncologists across the 
US, practicing for at least 2yrs and managing at least 20 patients, were randomly 
sampled to participate in a cross-sectional survey via a panel. Results: 231 phy-
sicians participated (87% physicians, 13% medical directors; 67.5% hematologist/
oncologists, 32.5% medical-oncologists; median age group 40-49yrs). Mean practice 
duration:15yrs; 53% practice in an academic/community/Veteran’s facility and 47% 
in group/solo private practice; 41% are part of an Accountable Care Organization 
(ACO); 89% use electronic health records (EHR). The most common QOC metric 
used was patient satisfaction scores (60%), followed by Quality Oncology Practice 
Initiatives:43%, adherence to clinical pathways:36%, Physician Quality Reporting 
System:35%, Commission on Cancer standards:24%, other:11%, and CancerLinQ:3%; 
None/not-sure:13%. Overall, 81% stated that their organization’s quality measure-
ment and tracking procedures were “somewhat/highly effective” in terms of improv-
ing quality of care, outcomes, and cost-savings. Average of 76% of cancer patients 
were reported to generally adhere to NCCN guidelines/pathways in the organization; 
84% were reported to have documented clinical/pathologic staging prior to initia-
tion of treatment (87% among non-ACO physicians, 80% among ACO physicians; 
p= 0.04). Use of at least one quality metric was more common among physicians 
participating in an ACO (93% vs. 83%; p= 0.04). Use of patient satisfaction scores was 
more common among physicians using EHR (62% vs. 42%; p= 0.048). cOnclusiOns: 
Standard QOC metrics for cancer care appear to be underutilized and appear to vary 
based on an affiliation with an ACO or use of EHR. Impact of observed patterns on 
patient care delivery/outcomes warrants scrutiny.
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Objectives: The Prostate Cancer Registry (NCT02236637) is an international, pro-
spective, observational study of mCRPC patients. One purpose is to evaluate the 
impact of mCRPC treatment on MRU in routine practice. MethOds: Patients were 
enrolled upon initiation of mCRPC treatment or during surveillance in > 150 centres 
across 16 countries. Baseline MRU was collected for 1 year before enrolment, and 
then prospectively at 3-month intervals. Baseline data were converted to a 3-month 
average to align with prospectively-collected data. We analyzed the MRU parameters 
of outpatient visits and hospitalization days at three months after treatment ini-
tiation. Results: We report data from 505 patients who were post-chemotherapy 
(n= 209) or chemotherapy-naïve (n= 296), with mean age 71.5 years and mean time 
since diagnosis 5.7 years. At baseline, MRU was greater for post-chemotherapy vs 
chemotherapy-naïve patients; mean total outpatient visits: 4.8 (range: 0-18) vs 2.5 
(range: 0-13) and mean total hospitalization days: 1.1 (range: 0-15) vs 0.6 (range: 0-8). 
For patients initiating new post-chemotherapy mCRPC treatment during follow-up 
(164/505 patients; 33%), MRU was analyzed by first treatment: abiraterone (n= 74), 
enzalutamide (n= 46), cabazitaxel (n= 44). In the first three months, mean (SD) and 
median [range] number of outpatient visits among patients with evaluable data 
were 4.2 (2.96) and 4.0 [0-13] for abiraterone (n= 51 patients with evaluable data); 
4.3 (2.94) and 4.2 [0-14] for enzalutamide (n= 32); and 7.6 (5.15) and 6.5 [1-30] for 
cabazitaxel (n= 38). During the same period, the mean (SD) number of hospitalization 
days was 2.6 (8.47) for abiraterone (n= 55); 2.2 (5.51) for enzalutamide (n= 33); and 1.5 
(3.94) for cabazitaxel (n= 40). Median number of hospitalization days was zero across 
treatments indicating < 50% of patients required hospitalization. cOnclusiOns: 
As these real-world data mature, the impact of different routine mCRPC treatments 
on MRU across multiple countries, medical disciplines and clinical settings may 
provide valuable insights to benefit patient care.
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Objectives: Radiation oncology is a key therapeutic strategy in cancer care. In 
order to assess the gap between the actual use of this therapy and evidence-based 
indications, we compare the number of new cancer patients that will require at 
least one course of radiotherapy in 24 European countries to its actual use, and 
project the results to 2020. MethOds: Incidence from each cancer type estimated 
by the European Cancer Observatory for 2012 was used in combination with the 
stages at diagnosis from five population-based cancer registries. Projections of can-
cer incidence to 2020 were also used. These data were applied to evidence-based 
decision trees for all tumors to calculate the Optimal Utilization Proportion (OUP). 
Data on actual use come from national radiotherapy societies. Results: Average 
OUP in European countries was 51% with a range from 47% (Russian Federation) 
to 53% (Belgium). The median actual use of radiotherapy was 69% of the OUP in 
the 24 countries analyzed. Only four countries showed an actual use higher than 
80% of the OUP. Projection of cancer incidence to 2020 showed a 10.1% increase in 
the number of candidates for radiotherapy compared to 2012, with most western 
European countries with increases between 10 and 15%. In absolute number of 
patients, this means an increase of 154294 for the EU 27 countries in this 8 years 
period. cOnclusiOns: The gap between optimal and actual use of radiotherapy 
poses a challenge to policy makers when planning future therapeutic resources. 
In order to reduce the gap, the focus on accessibility, reimbursement policies and 
multidisciplinary team clinical decision-making is mandatory. Also, there is a need 
to set reasonable targets that help pave the way to optimal use, keeping in mind the 
challenges which might make the OUP difficult to achieve.
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Objectives: Most policy decisions have a spatial component that can be integrated 
in formal decision making using geographic information systems (GIS) and multi-
criteria decision analysis (MCDA). However, GIS-MCDA is not commonly used in 
a health (economic) policy setting. The aim of this study is to introduce the spa-
tial component of healthcare policy decisions and to illustrate an application of 
GIS-MCDA using a case on comparing lung cancer screening versus smoking preven-
tion programs in the Netherlands. MethOds: Demographic data and data concern-
ing the distribution of persons at-risk of developing lung cancer were obtained from 
the Statistics Netherlands institute and aggregated per public health service (GGD) 
region. Effectiveness and costs data were obtained from literature and assumed to 
differ across population subgroups. The simple multi-attribute rating technique 
(SMART) method of MCDA was used. The GIS-MCDA model was built using ArcGIS 
software. Results: The effectiveness of either a screening or a prevention pro-
gram differed substantially across the GGD regions, reflecting differences in age 
distribution and percentage of young and old smokers. Considering the adjacency 
of regions, a different policy may be optimal for the north-east region (preven-
tion) and the south-west region (screening), but this may raise ethical questions of 
equity. Sensitivity analyses reveal that the decision is sensitive to the percentage 
of older smokers in a region and the relative cost of screening versus prevention. 
Limitations of the study are that the costs of implementation are not taken into 
account, that the time horizon was limited and that a non-exhaustive set of criteria 
was used. cOnclusiOns: GIS-MCDA can be a useful method to gain insight into 
the spatial component of healthcare policy decisions. Further research is required 
into including elicited preference data into the model, into including uncertainty 
in model parameters more formally and into selecting sets of alternatives (e.g. 
screening locations) based on a GIS-MCDA analysis.
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Objectives: Breakthrough innovation in oncology is commonly considered to be 
a substantial increase in overall survival (OS) above specific thresholds. However, 
this growing emphasis on significant OS gain, undervalues new products and may 
not capture aspects of treatment that are important to patients, including qual-
ity of life, delayed progression or improvements in side-effect profiles. We argue 
that progressive innovation in clinical and non-clinical domains needs to be con-
sidered and valued in regulatory and health technology assessment (HTA) deci-
sions. MethOds: Definitions of innovation used in regulatory, HTA, and industry 
were reviewed in the academic and gray literature and current/proposed OS thresh-
olds applied to therapies in colorectal cancer (CRC) and non-small cell lung cancer 
(NSCLC). Results: Regulators and HTA agencies do not provide clear consistent 
definitions of innovation; however, the magnitude of OS benefit is a consistent key 
aspect from both policy (e.g., England’s Cancer Drugs Fund) and clinical perspec-
tives (e.g., ASCO). Emphasis is on “clinically meaningful” change expressed as mini-
mum thresholds: OS gain > 2.5months; HR > 0.8; PFS gain > 3 months, HR > 0.5.. Only 
one of six CRC drugs approved since 2000 met these thresholds (ASCO; Ellis et al. 
2014) although survival has doubled in that time. No NSCLC products have met the 
threshold since 2005 whereas survival in first line treatment for advanced disease 
has doubled. cOnclusiOns: Innovation should be judged in relation to the value 
provided to patients and health systems, and should not be restricted to one-time 
large survival gains. Smaller sequential clinical gains and improved quality of life, 
safety, convenience, and system efficiency should also be considered. Progressive 
